Real-world treatment switching patterns in patients (pts) with type 2 diabetes mellitus (T2DM) on basal insulin (INS)

被引：0
|
作者：
Kapustin, J. [1 ]
Anderson, J. E. [2 ]
Reid, T. [3 ]
Rhinehart, A. [4 ]
Brunton, S. [5 ]
Stewart, J. [6 ]
Zhou, W. [6 ]
Dex, T. [7 ]
Kazemi, M. [7 ]
Vlajnic, A. [7 ]
Dalal, M. [7 ]
机构：
[1] Univ Maryland, Sch Nursing, Baltimore, MD 21201 USA
[2] Frist Cliln, Nashville, TN USA
[3] Mercy Diabet Ctr, Janesville, WI USA
[4] Johnston Mem Diabet Care Ctr, Abingdon, VA USA
[5] Primary Care Educ Consortium, Charlotte, NC USA
[6] Sanofi Canada, Laval, PQ, Canada
[7] Sanofi US, Bridgewater, MA USA
来源：
DIABETOLOGIA | 2014年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1070
引用
收藏
页码：S440 / S440
页数：1
相关论文
共 50 条
  • [31] Electronic Data Capture in Insulin Management for Patients (pts) with Type 1 (T1DM) and Type 2 (T2DM) Diabetes Mellitus in Global Clinical Trials
    Bastyr, Edward J., III
    Chang, Anne M.
    Mou, Jiani
    Bue-Valleskey, Juliana
    Hamilton, Robert T.
    Lesniewski, Scott J.
    Zhang, Shuyu
    Prince, Melvin J.
    DIABETES, 2014, 63 : A233 - A234
  • [32] Remogliflozin in Indian T2DM Patients: A Real-World Study
    Bhattacharya, Supratik
    Katare, Sagar
    DIABETES, 2020, 69
  • [33] USE OF HEDIS A1C TARGETS IN CHARACTERIZING TREATMENT GOALS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INITIATING BASAL INSULIN
    Oster, G.
    Moen, D.
    Yang, T.
    Dalal, M.
    Kazemi, M.
    Sung, J. C.
    Traylor, L.
    Sullivan, S. D.
    VALUE IN HEALTH, 2015, 18 (03) : A70 - A70
  • [34] Differences between Randomized Controlled Trial (RCT) and Real-World Type 2 Diabetes Mellitus (T2DM) Patients: Insights from Pooled Analysis of Insulin Glargine RCTs
    Rhinehart, Andrew S.
    Reid, Timothy
    Anderson, John E.
    Vlajnic, Aleksandra
    Stewart, John
    Dalal, Mehul
    Johnstone, Bryan
    Cuddihy, Robert
    DIABETES, 2013, 62 : A653 - A653
  • [35] Factors Associated with Basal Insulin Persistence after Initiation among People with Type 2 Diabetes Mellitus (T2DM)
    Desai, Urvi
    Kabul, Samaneh
    Ivanova, Jasmina I.
    Kirson, Noam Y.
    Cummings, Alice Kate
    Ristovska, Ljubica
    Birnbaum, Howard G.
    Hadjiyianni, Irene
    Duan, Ran
    Cao, Dachuang
    Perez-Nieves, Magaly
    DIABETES, 2015, 64 : A223 - A223
  • [36] Efficacy of metformin alone or in combination with insulin in pediatric patients with type 2 diabetes mellitus (T2DM)
    Weinzimer, SA
    McKnight, WJ
    Murphy, K
    Jawad, AF
    Celona-Jacobs, N
    Haque, A
    Katz, LEL
    DIABETES, 2001, 50 : A68 - A68
  • [37] GLYCATED HEMOGLOBIN (HBA1C) CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) TREATED WITH CANAGLIFLOZIN IN A REAL-WORLD SETTING
    Lefebvre, P.
    Pilon, D.
    Robitaille, M.
    Lafeuille, M.
    Chow, W.
    Pfeifer, M.
    Duh, M. S.
    VALUE IN HEALTH, 2015, 18 (03) : A57 - A57
  • [38] Real-world 12-month outcomes of patients with type 2 diabetes mellitus (T2DM) treated with canagliflozin in a US managed care setting
    Chow, Wing
    Buysman, Erin
    Rupnow, Marcia
    Anderson, Amy
    Henk, Henry
    Fegade, Mayuresh
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S118 - S118
  • [39] Real-World 12-Month Outcomes of Patients with Type 2 Diabetes Mellitus (T2DM) Treated with Canagliflozin in a US Managed Care Setting
    Chow, Wing
    Buysman, Erin K.
    Rupnow, Marcia F. T.
    Anderson, Amy J.
    Henk, Henry J.
    DIABETES, 2016, 65 : A321 - A321
  • [40] Augmentation Patterns Amongst Metformin Initiators with Type 2 Diabetes Mellitus (T2DM)
    Gopalakrishnan, Chandrasekar
    Schneeweiss, Sebastian
    Seeger, John D.
    Liu, Jun
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 26 - 27
12345